Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Pulmonary Diseases
NCT05147688Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Dec 2021
- Primary completion
- Dec 2028
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in pulmonary disease, asthma and chronic obstructive pulmonary disease (COPD), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Dec 2021; status: recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
pulmonary diseaseasthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05147688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147688.